Ozempic Label Updates 2020-2026: A Complete FDA Regulatory Timeline

How Ozempic Reached the Market

The FDA approved Ozempic on December 5, 2017, based on the SUSTAIN clinical trial program, granting semaglutide a once-weekly subcutaneous injection indication for improving glycemic control in adults with type 2 diabetes [1]. The original label covered 0.25 mg (for dose titration), 0.5 mg, and 1 mg strengths.

At launch, the prescribing information already carried a boxed warning about thyroid C-cell tumors based on rodent studies. The Warnings and Precautions section listed pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant insulin or sulfonylurea use, acute kidney injury, hypersensitivity reactions, and a contraindication in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [1]. The SUSTAIN-1 trial (N=388) had demonstrated a 1.5% mean HbA1c reduction with semaglutide 1 mg versus 0.0% with placebo, providing the key efficacy backbone [2].

Between approval and early 2020, the label underwent minor administrative revisions. The substantial changes began accumulating in 2020 as real-world prescribing data expanded and new SUSTAIN substudies reported outcomes.

The 2 mg Dose Expansion in March 2022

FDA approved the 2 mg once-weekly dose on March 16, 2022, giving prescribers a higher-strength option for patients who needed additional glycemic control beyond the 1 mg dose [3]. This was a meaningful label expansion. The approval rested on the SUSTAIN FORTE trial (N=961), which compared semaglutide 2 mg to 1 mg in adults with type 2 diabetes inadequately controlled on 1 mg.

SUSTAIN FORTE showed that the 2 mg dose reduced HbA1c by 2.2% from baseline versus 1.9% with 1 mg at 40 weeks [3]. Body weight dropped by 6.9 kg with 2 mg compared to 6.0 kg with 1 mg. The safety profile was consistent with lower doses: gastrointestinal adverse events (nausea, vomiting, diarrhea) were the most common treatment-emergent complaints, occurring in approximately 34% of the 2 mg group [3].

The label revision accompanying this approval updated dosing tables, pharmacokinetic parameters, and the Clinical Studies section. Novo Nordisk also introduced a new pen injector configuration to deliver the 2 mg dose, which required updated device instructions in the prescribing information.

Thyroid C-Cell Tumor Boxed Warning: What Has Changed

The boxed warning has remained structurally stable since 2017, but FDA has periodically updated the supporting language in Section 5.1 (Warnings and Precautions) and Section 13.1 (Nonclinical Toxicology) [1]. Semaglutide caused dose-dependent thyroid C-cell tumors in rats and mice at clinically relevant exposures. The relevance to humans remains undetermined.

The FDA's position, stated in the original approval review, is direct: "Semaglutide caused dose-dependent and treatment-duration-dependent increases in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in both genders of rats and mice" [1]. No confirmed cases of MTC attributable to semaglutide have been reported in clinical trials or post-market surveillance through 2025, though the FAERS database includes a small number of MTC reports that remain under evaluation [4].

A 2024 population-based cohort study published in The BMJ (N=145,410 GLP-1 receptor agonist users) found no statistically significant increase in thyroid cancer risk with GLP-1 RA use compared to DPP-4 inhibitors over a median follow-up of 3.9 years (HR 0.93, 95% CI 0.66-1.31) [5]. This study did not prompt a label change but contributed to the ongoing FDA Sentinel surveillance initiative monitoring this signal.

Gastrointestinal and Gallbladder Label Revisions

Gastrointestinal side effects are the most frequently reported adverse events with Ozempic. The original label documented nausea (15.8%-20.3%), diarrhea (8.5%-8.8%), vomiting (5.0%-9.2%), and constipation (3.1%-5.0%) across the SUSTAIN program [1]. These rates were established in controlled trials, and real-world reporting has remained broadly consistent.

The gallbladder-related changes are more significant. Between 2022 and 2023, FDA updated the Warnings and Precautions section to include cholelithiasis (gallstones) and cholecystitis based on post-marketing reports and pooled trial data [6]. In the SUSTAIN trials, cholelithiasis occurred in 1.5% of semaglutide-treated patients versus 0.4% of placebo-treated patients. The label now recommends that prescribers inform patients about signs and symptoms of gallbladder disease and consider gallbladder studies if clinically indicated.

Dr. Caroline Apovian, who served on the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, noted in 2023: "The gallbladder signal with GLP-1 receptor agonists is a class effect likely driven by rapid weight loss and altered bile acid metabolism, not a direct drug toxicity." This observation aligns with the established association between rapid weight reduction and gallstone formation regardless of method [7].

Intestinal Obstruction Warning Added in 2023

In September 2023, FDA updated the Ozempic label to include ileus (intestinal obstruction) in the Postmarketing Experience section [8]. This change followed a safety review of post-marketing reports submitted through FAERS.

The addition was notable because ileus was not identified as a risk in the SUSTAIN clinical trial program. GLP-1 receptor agonists slow gastric emptying as part of their mechanism of action. In some patients, particularly those with pre-existing gastrointestinal dysmotility conditions or concurrent use of medications that reduce intestinal motility (opioids, anticholinergics), this effect may contribute to obstruction [8].

The FDA did not issue a standalone safety communication for this update. It appeared as part of a routine label revision cycle. Prescribers should evaluate patients presenting with severe abdominal pain, constipation, or vomiting on semaglutide for possible bowel obstruction, especially those with prior abdominal surgery or gastroparesis history.

Diabetic Retinopathy Complications

Diabetic retinopathy complications have been part of the Ozempic label since its initial approval, based on findings from the SUSTAIN-6 cardiovascular outcomes trial (N=3,297) [9]. In SUSTAIN-6, the rate of retinopathy complications (vitreous hemorrhage, blindness, or conditions requiring treatment with an intravitreal agent or photocoagulation) was 3.0% with semaglutide versus 1.8% with placebo (HR 1.76, 95% CI 1.11-2.78) [9].

The FDA label includes a specific warning stating that rapid improvement in glucose control may temporarily worsen diabetic retinopathy, and that patients with a history of diabetic retinopathy should be monitored [1]. This language has been refined across label revisions but the core warning has persisted.

The FOCUS trial, a dedicated ophthalmologic outcomes study, was designed to address this signal more definitively. In 2024, topline results from FOCUS (N=1,328) showed no significant worsening of diabetic retinopathy with semaglutide compared to placebo over 5 years [10]. Novo Nordisk submitted these data to FDA. As of mid-2026, the label still retains the diabetic retinopathy warning pending completion of the full regulatory review.

The Endocrine Society's 2024 Clinical Practice Guideline on pharmacologic management of type 2 diabetes states: "Clinicians should monitor patients with pre-existing diabetic retinopathy who are initiated on GLP-1 receptor agonists, particularly during rapid glucose improvement phases" [11].

Acute Kidney Injury and Renal Warnings

The original Ozempic label included acute kidney injury (AKI) as a warning, primarily linked to dehydration from gastrointestinal adverse events (nausea, vomiting, diarrhea) [1]. Post-marketing revisions in 2022 strengthened this language, adding more detail about cases reported in patients without known pre-existing renal disease [12].

Between 2017 and 2025, FAERS received over 3,200 reports of renal and urinary disorders associated with semaglutide products (Ozempic and Wegovy combined) [4]. The majority involved patients experiencing dehydration secondary to gastrointestinal symptoms rather than direct nephrotoxicity.

A 2023 retrospective cohort study published in JAMA Internal Medicine (N=2,375,910) actually found a lower risk of AKI among GLP-1 RA users compared to DPP-4 inhibitor users (HR 0.84, 95% CI 0.78-0.90) [13]. This study examined semaglutide, liraglutide, and dulaglutide collectively. The finding suggests that while dehydration-related AKI is a real risk, GLP-1 receptor agonists may have a net renal benefit in appropriately hydrated patients.

The current label advises monitoring renal function in patients who report severe gastrointestinal reactions and recommends dose reduction or discontinuation if clinically significant renal impairment develops.

Cardiovascular Outcomes and SELECT Trial Implications

The SELECT trial (N=17,604) studied semaglutide 2.4 mg (the Wegovy dose, not Ozempic) in adults with overweight or obesity and established cardiovascular disease but without diabetes [14]. Published in November 2023, SELECT showed a 20% reduction in major adverse cardiovascular events (MACE) with semaglutide versus placebo (HR 0.80, 95% CI 0.72-0.90) over a median 39.8 months [14].

While SELECT data supported the cardiovascular indication for Wegovy (approved March 2024), the Ozempic label has not been updated with a cardiovascular risk reduction indication as of mid-2026. The distinction matters. Ozempic's doses (0.5-2 mg) differ from Wegovy's (2.4 mg), and the SELECT population excluded patients taking semaglutide for diabetes. The existing cardiovascular outcomes data for Ozempic come from SUSTAIN-6, which showed non-inferiority to placebo for MACE (HR 0.74, 95% CI 0.58-0.95) but was not powered for superiority [9].

SUSTAIN-7 (N=1,201) compared semaglutide to dulaglutide head-to-head, demonstrating superior HbA1c reduction (1.8% vs 1.4% with highest doses) and greater weight loss (6.5 kg vs 3.0 kg) at 40 weeks [15]. These data appear in the Clinical Studies section of the label and support dose selection, though they do not directly affect the warnings or precautions.

Post-Market Surveillance and FDA Sentinel

FDA monitors Ozempic through multiple post-market channels. The Sentinel System, which accesses data from over 100 million patients across participating health plans, runs active surveillance queries for GLP-1 receptor agonist safety signals [16]. FAERS receives voluntary reports from healthcare professionals, patients, and manufacturers.

Key signals under active Sentinel monitoring as of 2025-2026 include thyroid cancer (ongoing, as discussed above), pancreatic cancer, and suicidal ideation or behavior [16]. In January 2024, FDA completed a preliminary evaluation of suicidality reports with GLP-1 RAs and concluded that "available evidence does not indicate a causal association between use of GLP-1 receptor agonists and suicidal ideation or actions" [17]. The Ozempic label has not been updated with a suicidality warning.

The European Medicines Agency (EMA) conducted a parallel review through its Pharmacovigilance Risk Assessment Committee (PRAC) and reached a similar conclusion in April 2024, finding no causal link between GLP-1 RAs and suicidal thoughts [18].

FDA's Dr. Patrizia Cavazzoni stated in 2024: "We will continue to monitor these safety signals and will take further action as needed based on our ongoing evaluation of the available data" [17].

Reading the Current Prescribing Information

The Ozempic prescribing information runs 44 pages as of its most recent revision. For prescribers and patients trying to interpret changes, several sections deserve attention.

Section 5 (Warnings and Precautions) is where most label changes appear. The current version lists: thyroid C-cell tumors, pancreatitis, diabetic retinopathy complications, hypoglycemia with concomitant insulin secretagogues, acute kidney injury, hypersensitivity reactions, acute gallbladder disease, and intestinal obstruction [1]. Each warning includes the clinical trial incidence data that triggered the label language and, where applicable, post-marketing case descriptions.

Section 6.2 (Postmarketing Experience) has expanded the most since 2020. This section now includes gastrointestinal disorders (ileus), hepatobiliary disorders (cholelithiasis, cholecystitis), and renal and urinary disorders (worsening of chronic renal failure) [1].

Prescribers should review the full label at FDA Drugs@FDA at least annually, as label supplements can be approved without formal safety communications. The Ozempic NDA number is 209637.